Literature DB >> 31071072

Increase in Hepatitis A Virus Infections - United States, 2013-2018.

Monique A Foster1, Megan G Hofmeister1, Benjamin A Kupronis1, Yulin Lin1, Guo-Liang Xia1, Shaoman Yin1, Eyasu Teshale1.   

Abstract

Hepatitis A virus (HAV) is primarily transmitted fecal-orally after close contact with an infected person (1); it is the most common cause of viral hepatitis worldwide, typically causing acute and self-limited symptoms, although rarely liver failure and death can occur (1). Rates of hepatitis A had declined by approximately 95% during 1996-2011; however, during 2016-2018, CDC received approximately 15,000 reports of HAV infections from U.S. states and territories, indicating a recent increase in transmission (2,3). Since 2017, the vast majority of these reports were related to multiple outbreaks of infections among persons reporting drug use or homelessness (4). In addition, increases of HAV infections have also occurred among men who have sex with men (MSM) and, to a much lesser degree, in association with consumption of imported HAV-contaminated food (5,6). Overall, reports of hepatitis A cases increased 294% during 2016-2018 compared with 2013-2015. During 2016-2018, CDC tested 4,282 specimens, of which 3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 (84%), and 57 (<1%) of these specimens were genotype IA, IB, or IIIA, respectively. Adherence to the Advisory Committee on Immunization Practices (ACIP) recommendations to vaccinate populations at risk can help control the current increases and prevent future outbreaks of hepatitis A in the United States (7).

Entities:  

Mesh:

Year:  2019        PMID: 31071072      PMCID: PMC6542191          DOI: 10.15585/mmwr.mm6818a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Hepatitis A virus (HAV) is primarily transmitted fecal-orally after close contact with an infected person (); it is the most common cause of viral hepatitis worldwide, typically causing acute and self-limited symptoms, although rarely liver failure and death can occur (). Rates of hepatitis A had declined by approximately 95% during 1996–2011; however, during 2016–2018, CDC received approximately 15,000 reports of HAV infections from U.S. states and territories, indicating a recent increase in transmission (,). Since 2017, the vast majority of these reports were related to multiple outbreaks of infections among persons reporting drug use or homelessness (). In addition, increases of HAV infections have also occurred among men who have sex with men (MSM) and, to a much lesser degree, in association with consumption of imported HAV-contaminated food (,). Overall, reports of hepatitis A cases increased 294% during 2016–2018 compared with 2013–2015. During 2016–2018, CDC tested 4,282 specimens, of which 3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 (84%), and 57 (<1%) of these specimens were genotype IA, IB, or IIIA, respectively. Adherence to the Advisory Committee on Immunization Practices (ACIP) recommendations to vaccinate populations at risk can help control the current increases and prevent future outbreaks of hepatitis A in the United States (). Hepatitis A infections among persons who meet the Council of State and Territorial Epidemiologists (CSTE) hepatitis A case definition (https://wwwn.cdc.gov/nndss/conditions/hepatitis-a-acute/) are notified to CDC through the National Notifiable Diseases Surveillance System (NNDSS). Cases reported to CDC through NNDSS during 2013–2018 were used to calculate percent change (2013–2015 versus 2016–2018) by state and mapped using RStudio software (version 1.2.1335; RStudio, Inc.). Serum specimens from CSTE confirmed cases submitted to the CDC laboratory were tested for HAV RNA by polymerase chain reaction, and isolated virus was amplified to characterize a 315–base-pair fragment of the VP1/P2B region, which defines the genotype of the virus. Overall, reports of hepatitis A cases increased 294% during 2016–2018 compared with 2013–2015 (Figure). Eighteen states had lower case counts during 2016–2018 compared with 2013–2015. Nine states and Washington, DC had an increase of approximately 500%. During 2013–2018, 4,508 HAV anti-immunoglobulin M–positive specimens underwent additional testing at CDC. During 2013–2015, 226 specimens underwent additional testing, of which 197 (87%) had detectable HAV RNA; of the RNA-positive specimens, 76 (39%), 121 (61%), and 0 (0%) tested positive for a genotype IA, IB, or IIIA viral strain, respectively. In comparison, 4,282 specimens were tested by CDC during 2016–2018, of which 3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 (84%), and 57 (<1%) of these specimens were genotype IA, IB, or IIIA, respectively.
FIGURE

Percent change in reported hepatitis A infections, by state — National Notifiable Diseases Surveillance System, United States, 2013–2015 and 2016–2018*

Abbreviation: DC = District of Columbia.

* 2017 and 2018 case counts are provisional.

Percent change in reported hepatitis A infections, by state — National Notifiable Diseases Surveillance System, United States, 2013–2015 and 2016–2018* Abbreviation: DC = District of Columbia. * 2017 and 2018 case counts are provisional.

Discussion

The number of hepatitis A infections reported to CDC increased during 2016–2018, along with the number of specimens from infected persons submitted to CDC for additional testing. In the past, outbreaks of hepatitis A virus infections occurred every 10–15 years and were associated with asymptomatic children (). With the widespread adoption of universal childhood vaccination recommendations (https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm), asymptomatic children are no longer the main drivers of hepatitis A outbreaks (,). Although the overall incidence rate of HAV infections has decreased within all age groups, a large population of susceptible, unvaccinated adults who were not infected by being exposed to the virus during childhood remain vulnerable to infection by contaminated foods (typically imported from countries with endemic HAV transmission) and recently, on a much larger scale, through behaviors that increase risk for infection in certain vulnerable populations, such as drug use (). Increasingly, molecular epidemiology is employed by public health laboratories to better characterize hepatitis A transmission patterns. When combined with reliable epidemiologic data, these laboratory data can be used to identify transmission networks and confirm the source of exposure during common-source outbreaks, facilitating prompt and effective public health response. Historically, genotype IA has been the most common genotype circulating in North and South America. During 2013–2018, HAV genotype IB predominated in the United States. Increasing numbers of genotype IIIA were seen, a genotype that is considered rare in the United States. Decreasing new infections from hepatitis A virus can be achieved and sustained by maintaining a high level of population immunity through vaccination. There is no universal vaccination recommendation for adults in the United States; however, ACIP does recommend vaccination for adults who plan travel to HAV-endemic countries, MSM, persons who use drugs, persons with chronic liver disease, and recently, persons experiencing homelessness (). Continued efforts to increase hepatitis A vaccination coverage among the ACIP-recommended risk groups is vital to halting the current hepatitis A outbreaks and reducing overall hepatitis A incidence in the United States.

What is already known about this topic?

Hepatitis A is a vaccine-preventable viral infection of the liver that is primarily transmitted through consumption of microscopic amounts of feces.

What is added by this report?

During 2016–2018, reports of hepatitis A infections in the United States increased by 294% compared with 2013–2015, related to outbreaks associated with contaminated food items, among men who have sex with men, and primarily, among persons who report drug use or homelessness.

What are the implications for public health practice?

Increasing vaccination among groups at risk for hepatitis A infection might halt ongoing outbreaks and prevent future outbreaks.
  7 in total

1.  Progress Toward Eliminating Hepatitis A Disease in the United States.

Authors:  Trudy V Murphy; Maxine M Denniston; Holly A Hill; Marian McDonald; Monina R Klevens; Laurie D Elam-Evans; Noele P Nelson; John Iskander; John D Ward
Journal:  MMWR Suppl       Date:  2016-02-12

2.  Decreasing immunity to hepatitis A virus infection among US adults: Findings from the National Health and Nutrition Examination Survey (NHANES), 1999-2012.

Authors:  R Monina Klevens; Maxine M Denniston; Ruth B Jiles-Chapman; Trudy V Murphy
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

3.  Public health investigation and response to a hepatitis A outbreak from imported scallops consumed raw-Hawaii, 2016.

Authors:  M A Viray; M G Hofmeister; D I Johnston; V P Krishnasamy; C Nichols; M A Foster; R Balajadia; M E Wise; A Manuzak; Y Lin; G Xia; C Basler; J Nsubuga; J Woods; S Y Park
Journal:  Epidemiol Infect       Date:  2018-10-17       Impact factor: 2.451

4.  Hepatitis A: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Cristina Meleleo; Laura Serino; Debora Sorbara; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

5.  Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men - New York City, January-August 2017.

Authors:  Julia Latash; Marie Dorsinville; Paula Del Rosso; Mike Antwi; Vasudha Reddy; HaeNa Waechter; Jacqueline Lawler; Heather Boss; Philip Kurpiel; P Bryon Backenson; Charles Gonzalez; Shannon Rowe; Tasha Poissant; Yulin Lin; Guo-Liang Xia; Sharon Balter
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-09-22       Impact factor: 17.586

6.  Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness.

Authors:  Mona Doshani; Mark Weng; Kelly L Moore; José R Romero; Noele P Nelson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-02-15       Impact factor: 17.586

7.  Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017.

Authors:  Monique Foster; Sumathi Ramachandran; Katie Myatt; Danielle Donovan; Susan Bohm; Jay Fiedler; Bree Barbeau; Jim Collins; Douglas Thoroughman; Eric McDonald; Jonathan Ballard; Jeffrey Eason; Cynthia Jorgensen
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-11-02       Impact factor: 17.586

  7 in total
  34 in total

Review 1.  The History of Hepatitis A.

Authors:  Daniel Shouval
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-10-07

2.  New Subgenotyping and Consensus Real-Time Reverse Transcription-PCR Assays for Hepatitis A Outbreak Surveillance.

Authors:  William S Probert; Jill K Hacker
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

Review 3.  Treatment and prevention of viral hepatitis in pregnancy.

Authors:  Jodie Dionne-Odom; Gabriella D Cozzi; Ricardo A Franco; Basile Njei; Alan T N Tita
Journal:  Am J Obstet Gynecol       Date:  2021-09-10       Impact factor: 8.661

4.  Biochemical and structural characterization of hepatitis A virus 2C reveals an unusual ribonuclease activity on single-stranded RNA.

Authors:  Pu Chen; Justyna Aleksandra Wojdyla; Ombretta Colasanti; Zhijian Li; Bo Qin; Meitian Wang; Volker Lohmann; Sheng Cui
Journal:  Nucleic Acids Res       Date:  2022-08-10       Impact factor: 19.160

5.  Behavioral Intentions to Use Patient Portals to Disclose HIV and Other Sexually Transmitted Infection Testing Histories with Sexual Partners Among U.S. Sexual Minority Men.

Authors:  Kevon-Mark Jackman; Derek T Dangerfield; Cui Yang; Maria Trent; Hadi Kharrazi; Renee M Johnson; Carl Latkin
Journal:  AIDS Behav       Date:  2020-11-13

6.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

7.  Update on Hepatitis A Management.

Authors:  Mark K Weng; Aaron M Harris; Noele P Nelson
Journal:  JAMA       Date:  2021-01-26       Impact factor: 56.272

8.  T cells protect against hepatitis A virus infection and limit infection-induced liver injury.

Authors:  Ichiro Misumi; Joseph E Mitchell; Makayla M Lund; John M Cullen; Stanley M Lemon; Jason K Whitmire
Journal:  J Hepatol       Date:  2021-07-29       Impact factor: 25.083

9.  Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018.

Authors:  Monique A Foster; Megan G Hofmeister; Justin P Albertson; Kerri B Brown; Alexis W Burakoff; Ami P Gandhi; Rosie E Glenn-Finer; Prabhu Gounder; Po-Yi Ho; Tracy Kavanaugh; Julia Latash; Rebecca L Lewis; Atkinson G Longmire; Angela Myrick-West; Dana M Perella; Vasudha Reddy; Emma S Stanislawski; Juliet E Stoltey; Susan M Sullivan; Okey F Utah; Jennifer Zipprich; Eyasu H Teshale
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-06-18       Impact factor: 17.586

Review 10.  Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.

Authors:  Jessica L Taylor; Samantha Johnson; Ricardo Cruz; Jessica R Gray; Davida Schiff; Sarah M Bagley
Journal:  J Gen Intern Med       Date:  2021-06-22       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.